Emcure Pharmaceuticals Ltd (EMCURE) - Total Assets
Based on the latest financial reports, Emcure Pharmaceuticals Ltd (EMCURE) holds total assets worth Rs96.12 Billion INR (≈ $1.04 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Emcure Pharmaceuticals Ltd - Total Assets Trend (2022–2026)
This chart illustrates how Emcure Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. Also see Emcure Pharmaceuticals Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Emcure Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (March 2026)
Emcure Pharmaceuticals Ltd's total assets of Rs96.12 Billion consist of 58.4% current assets and 41.6% non-current assets. Review Emcure Pharmaceuticals Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.5% |
| Accounts Receivable | Rs25.63 Billion | 26.7% |
| Inventory | Rs23.98 Billion | 25.0% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs6.87 Billion | 7.2% |
| Goodwill | Rs4.14 Billion | 4.3% |
Asset Composition Trend (2022–2026)
This chart illustrates how Emcure Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See EMCURE live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Emcure Pharmaceuticals Ltd's current assets represent 58.4% of total assets in 2026, an increase from 56.5% in 2022.
- Cash Position: Cash and equivalents constituted 1.5% of total assets in 2026, up from 1.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 5.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 26.7% of total assets.
Emcure Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Emcure Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Natco Pharma Limited
NSE:NATCOPHARM
|
India | Rs104.30 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
Emcure Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.43 | 1.71 | 1.34 |
| Quick Ratio | 0.82 | 0.98 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs17.00 Billion | Rs18.88 Billion | Rs9.90 Billion |
Emcure Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Emcure Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.17 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 16.8% |
| Total Assets | Rs96.12 Billion |
| Market Capitalization | $4.00 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Emcure Pharmaceuticals Ltd's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Emcure Pharmaceuticals Ltd's assets grew by 16.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Emcure Pharmaceuticals Ltd (2022–2026)
The table below shows the annual total assets of Emcure Pharmaceuticals Ltd from 2022 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs96.12 Billion ≈ $1.04 Billion |
+16.76% |
| 2025-03-31 | Rs82.33 Billion ≈ $890.34 Million |
+5.46% |
| 2024-03-31 | Rs78.06 Billion ≈ $844.21 Million |
+16.99% |
| 2023-03-31 | Rs66.73 Billion ≈ $721.61 Million |
+10.04% |
| 2022-03-31 | Rs60.63 Billion ≈ $655.74 Million |
-- |
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure X… Read more